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Identity 
Other names: PPP1R6, PPP1R9, SPINO, Spn 
HGNC (Hugo): PPP1R9B 
Location: 17q21.33 
DNA/RNA 
See the scheme of the 17q21 locus below. 
Protein 
Description 
PPP1R9B protein have different modular domains that 
govern protein-protein interactions (Sarrouilhe et al.,
2006). These domains include two F-actin-, three 
potential Src homology 3 (SH3)-, one receptor- and o e  
PP1-binding domains, one PDZ binding domain, three 
coiled-coil domains, and one potential 
leucine/isoleucine zipper motif.  
Many partner proteins of PPP1R9B have been 
described, including enzymes, guanine nucleotide 
exchange factors, cytoskeletal and cell adhesion 
molecules, membrane receptors, ion channels and G-
protein signaling protein regulators.  
PPP1R9B also regulates seven-transmembrane receptor 
signaling and may link these receptors to intracellular 
mitogenic signaling dependent on p70S6k and the Rac-
GEF. Accordingly, PPP1R9B may serve as a linker 
between actin cytoskeleton and transmembrane 
proteins, targeting PP1 to its targets and facilitating the 
coordination of the external signaling with the 
downstream pathway (Brady et al., 2003; Küntziger et 
al., 2011; Sarrouilhe et al., 2006; Vivo et al., 2001; 
Wang et al., 2004; Carnero, 2012). 
 
Scheme of the 17q21 locus. Adapted from Carnero, 2012. 
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Scheme of the PPP1R9B protein. Below bars indicate binding regions for proteins indicated. Adapted from Carnero, 2012. 
 
Expression 
PPP1R9B was detected predominantly in dendritic 
spines in prefrontal cortex and is enriched in cerebral 
cortex, caudatoputamen, hypocampal formation and 
cerebellum. But expression in most normal tissues is 
also clearly detected (Muly et al., 2004; Ouimet et al., 
2004).  
PPP1R9B protein is downrelulated in a great variety of 
human carcinomas but in a low percentage of tumors.  
Immunohistochemical analysis of PPP1R9B during 
cancer progression shows some correlation with 
tumoral progression and p53 mutations (Carnero, 
2012). 
Localisation 
In most tissues, with higher levels in neural system. 
Function 
The structure of PPP1R9B suggests that functions as a 
protein scaffold that regulates both membrane and 
cytoskeletal functions. PPP1R9B performs important 
functions in the nervous system where it is implicated 
in the regulation of spine morphology and density, 
synaptic plasticity and neuronal migration.  
PPP1R9B could serve as a link between excitatory 
synapse transmission and changes in spine morphology 
and density (Allen et al., 2006; Hsieh-Wilson et al., 
1999; Sarrouilhe et al., 2006). 
PPP1R9B is a key modulator of the opiate action. 
PPP1R9B also promotes endocytosis of the mu-opioid 
receptor (Charlton et al., 2008). 
PPP1R9B has been implicated through PP1 binding in 
the regulation of AMPA-type glutamate receptor. 
PPP1R9B may serve to regulate excitatory synaptic 
transmission and plasticity by targeting PP1 to its 
cellular substrates, promoting their downregulation by 
dephosphorylation regulating the post-synaptic 
glutaminergic neurotransmission.  
PKA modulation of the localization of the 
PPP1R9B/PP1 complex could contribute to this effect.  
Plasticity in dendritic spines may underlie learning and 
memory, and observations in PPP1R9B null mice 
shown that PPP1R9B plays a role in learning in vivo 
(Hsieh-Wilson et al., 2003; Stafstrom-Davis et al., 
2001; Yan et al., 1999). 
PPP1R9B also has a role in the regulation of blood 
pressure and cardiac function (da Costa-Goncalves et 
al., 2008). Since PPP1R9B can control the intensity and 
duration of the G-protein receptor signaling influencing 
synaptic activity, PPP1R9B affects blood pressure 
through central mechanisms. In adult cardiomyocytes it 
has been proposed that PPP1R9B is an upstream 
regulator required for normal growth and excitation-
contraction coupling, but is dispensable for b-
adrenergic stimulation (Petzhold et al., 2011).  
Association of PPP1R9B with the α2-AR leads to 
alteration of α2-AR phosphorylation following agonist 
stimulation, suggesting that Spn acts mainly as an 
antagonist of arrestin. Thus, PPP1R9B participates in 
the regulation of signaling duration and sensitivity of 
the α2-AR response therefore regulating smooth 
muscle contraction. Following agonist treatment, 
PPP1R9B competition with GRK for α2-AR also 
prevents α2-AR endocytosis. 
Finally, a role for PPP1R9B in the formation of 
immunological synapses in dendritic cells has also been 
proposed, and PPP1R9B may be involved in the 
maintenance of cellular architecture by regulating actin 




Expression levels decrease in some carcinomas. 
Oncogenesis 
PPP1R9B mRNA is lost in a percentage of renal 
carcinomas and lung adenocarcinomas (Carnero, 2012). 
More interestingly, analysis of normal vs tumoral 
samples of tumors of the CNS showed clear 
downregulation of PPP1R9B in tumoral samples.  
Furthermore, lower levels of PPP1R9B mRNA 
correlates with higher grade of ovarian carcinoma and
chronic myelogenous leukaemia (Carnero, 2012).  
PPP1R9B is also lost in 20% and reduced in another 
37% of human lung tumors (Molina-Pinelo et al., 
2011).  
PPP1R9B reduction correlates with malignant grade 
and p53 mutations (Carnero, 2012). 
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PPP1R9B expression in colon: left, normal epithelia with high levels PPPR1B; right, PPP1RB downregulation in carcinoma. 
 
The PPP1R9B gene is located in chromosome 17, at 
position 17q21.33, and in a cytogenetic area frequently 
associated with microsatellite instability and loss of 
heterozygosity.  
This region is comprised of a relatively high density of 
tumor suppressor genes, including known (BRCA1, 
NME1), putative (JUP, prohibitin), and unidentified 
candidates distal to the BRCA1 locus (Carnero, 2012). 
Most of the studies on the 17q21 locus have focused on 
BRCA1, which exhibits a variable frequency in LOH 
depending on the type of tumor, stage and marker 
employed, and has been extensively studied in breast 
carcinomas (Caduff et al., 1999; Maitra et al., 1999; 
Querzoli et al., 2001). However, there are few studies 
that suggest the existence of unknown tumor 
suppressor genes for breast tumors in an area that 
includes the locus of PPP1R9B.  
LOH in chromosome 17q21.3 has been observed in 
different tumors, including breast, ovarian, prostate, 
colorectal, gastric, renal and lung carcinomas, as well
as in salivary gland carcinosarcoma, an extremely 
aggressive neoplasm (Caduff et al., 1999; Maitra et l., 
1999; Querzoli et al., 2001). 
The markers used in some of these studies with no 
linkage to BRCA1 point to NME1 as a tumor 
suppressor gene candidate to justify the functional 
impact of the allelic loss.  
However, in different LOH studies an unidentified 
tumor suppressor gene nearby NME1 has been 
proposed.  
PPP1R9B is located in close proximity to NME1, at 
only 1 Mb, probably sharing the allelic loss in these 
studies. 
The most relevant data according to PPP1R9B LOH 
came from a study on primary lung carcinoma 
(Abujiang et al., 1998). This group performed an 
extensive LOH mapping in human lung cancers, using 
15 highly polymorphic markers, 7 of which span 
17q11-24 region. The higher LOH value appeared with
the D17S588 marker, showing a 53% of loss. The 
D17S588 marker locates exactly within the PPP1R9B 
locus. These data provided the first robust data 
implicating PPP1R9B LOH in cancer. Closer tumor 
suppressor genes, such as BRCA1, were not seriously 
affected (6-13% LOH), nor other lung proliferative 
pathologies (squamous cell carcinoma and small cell 
carcinoma only showed minimal LOH, below 14%, for 
both PPP1R9B and BRCA1 markers). 
Several genetic linkage studies using the marker 
D17S588 have suggested the existence of a tumor 
suppressor gene distal to BRCA1 (Porter et al., 1993; 
Porter et al., 1994). The maximum LOD scores 
obtained for D17S588 were of 5,44 in an Edinburgh 
study of 15 families (Cohen et al., 1993) and 21,68 in 
an analysis of 271 breast and breast-ovarian cancer 
families (Easton et al., 1993, Smith et al., 1993), 
indicating the importance of this locus in the pathology 
of cancer. The D17S588 marker lies inside the 
PPP1R9B gene. 
Another study that investigated the correlation betwe n 
p53 abnormalities and allelic loss of BRCA1, BRCA2 
and adjacent loci in breast cancer found a strong 
correlation when using the D17S588 marker (Querzoli 
et al., 2001; Tseng et al., 1997). Again, PPP1R9B may
be involved in the tumorigenic process by functioning, 
in association with a loss of p53 functionality, as  
tumor suppressor (47,1% LOH) (Tseng et al., 1997). 
Learning and memory, regulation of 
blood pressure and cardiac function 
Disease 
Learning and memory defects, problems in the 
regulation of blood pressure and cardiac function, 
tumors of different origin. 
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